Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Description

This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.

Conditions

Fecal Incontinence

Study Overview

Study Details

Study overview

This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.

A Two-stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel With Placebo in the Treatment of Female Participants With Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Condition
Fecal Incontinence
Intervention / Treatment

-

Contacts and Locations

La Jolla

UC San Diego Health, La Jolla, California, United States, 92122

Orange

UC Irvine Medical Center, Orange, California, United States, 92868

Tustin

Prestige Medical Group, Tustin, California, United States, 92780

Gainesville

University of Florida Shands Hospital, Gainesville, Florida, United States, 32610

Miami

Healthcare Clinical Data, Inc., Miami, Florida, United States, 33161

Orlando

Orlando Health Colon & Rectal Institute, Orlando, Florida, United States, 32806

Tampa

USF Health South Tampa Center for Advanced Healthcare, Tampa, Florida, United States, 33606

Fayetteville

Colorectal Wellness Center, Fayetteville, Georgia, United States, 30214

Chicago

University of Illinois, Chicago, Illinois, United States, 60612

Indianapolis

Franciscan Health Indianapolis, Indianapolis, Indiana, United States, 46237

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult female ≥ 18 years of age who has primary symptoms of fecal incontinence (FI) for at least 12 months.
  • * History of obstetric anal sphincter injury (e.g., episiotomy, perineal tear).
  • * Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment.
  • * Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures.
  • * Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician.
  • * Is pregnant or planning to become pregnant within the next 2 years.
  • * Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity).
  • * Has an obstetric anal sphincter injury (e.g., episiotomy, perineal tear) within 1 year previous to study enrollment.
  • * Patient BMI ≥ 38.
  • * Has a history of cancer in the colorectal or pelvic organs within 5 years prior to study enrollment.
  • * Any cancer that has undergone treatment within the past 12 months.
  • * Has an established diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or current intestinal stoma.
  • * Has grade III/IV hemorrhoids.
  • * Has chronic diarrhea at the time of Screening.
  • * Has chronic constipation at the time of Screening.
  • * Has significant pelvic floor prolapse, significant genitourinary prolapse beyond the introitus, significant symptomatic rectocele, or evidence of significant rectal evacuation disorder leading to post-defecatory leakage.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cook MyoSite,

Ron Jankowski, PhD, STUDY_DIRECTOR, Cook Myosite, Inc.

Study Record Dates

2027-09